You need to be logged in to see the full monograph.


Date of issue: July 2021, Version: 2

bumps logo
A corresponding patient information leaflet on USE OF USTEKINUMAB IN PREGNANCY is available.

Ustekinumab is a fully human IgG1κ monoclonal antibody to interleukin (IL)-12/23 produced using recombinant DNA technology. Ustekinumab is licensed for the management of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Some maternal autoimmune/inflammatory conditions are known to be associated with increased risk of certain adverse pregnancy outcomes, such as miscarriage, preterm delivery and low birth weight. Adequate control of the maternal condition may therefore decrease the risk of such adverse pregnancy outcomes; however, robust data to support this are not available.

Data regarding the safety of ustekinumab use in pregnancy are highly limited, consisting of 61 exposed pregnancies mostly described in uncontrolled studies where ustekinumab was generally discontinued in the first trimester.

The available data do not provide any signal to indicate that ustekinumab use in pregnancy increases the risk of miscarriage, malformation, intrauterine fetal death, preterm delivery, low birth weight or neurodevelopmental impairment. However, it is not currently feasible to provide a reliable evidence-based evaluation of the risk posed to the fetus due to the small number of exposed pregnancies described in the literature.

As ustekinumab is not expected to cross the placenta during the first trimester, congenital malformations due to a direct effect on the fetus would not be anticipated. However, indirect fetal effects cannot be excluded and, due to the lack of human pregnancy data, women who have been exposed to ustekinumab in early pregnancy should be strongly encouraged to attend their routine prenatal monitoring scans.

There is theoretical concern that the use of immunosuppressant antibodies that actively cross the placenta during pregnancy (including ustekinumab) could result in immunosuppression in the newborn and increased risk of infection. Guidance from Public Health England (PHE) [issued 2017] specifies that, following in utero biologic immunosuppressant exposure, live vaccines should not be used until the infant is 6 months old.

Due to the current lack of data, additional fetal monitoring may be warranted on a case-by-case basis. Other risk factors may be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments. Please report all cases of ustekinumab exposure to UKTIS.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from to ensure you are using the most up-to-date version.